Rockland Trust Co. Boosts Stock Position in Zoetis Inc. $ZTS

Rockland Trust Co. lifted its stake in Zoetis Inc. (NYSE:ZTS) by 27.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 203,771 shares of the company’s stock after purchasing an additional 43,616 shares during the quarter. Rockland Trust Co.’s holdings in Zoetis were worth $14,643,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ZTS. Trust Point Inc. boosted its stake in Zoetis by 9.2% during the second quarter. Trust Point Inc. now owns 4,912 shares of the company’s stock worth $353,000 after buying an additional 412 shares during the last quarter. Czech National Bank increased its stake in shares of Zoetis by 3.8% in the 2nd quarter. Czech National Bank now owns 119,328 shares of the company’s stock worth $8,575,000 after acquiring an additional 4,363 shares during the last quarter. PensionDanmark Pensionsforsikringsaktieselskab increased its stake in shares of Zoetis by 13.4% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 147,182 shares of the company’s stock worth $10,576,000 after acquiring an additional 17,340 shares during the last quarter. Byrne Asset Management LLC raised its holdings in shares of Zoetis by 55.8% during the 2nd quarter. Byrne Asset Management LLC now owns 670 shares of the company’s stock worth $48,000 after acquiring an additional 240 shares during the period. Finally, Sarasin & Partners LLP raised its holdings in shares of Zoetis by 5.6% during the 2nd quarter. Sarasin & Partners LLP now owns 22,570 shares of the company’s stock worth $1,622,000 after acquiring an additional 1,200 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 6.1%

Shares of ZTS stock opened at $72.53 on Friday. Zoetis Inc. has a 1-year low of $71.47 and a 1-year high of $160.48. The firm has a market cap of $30.41 billion, a PE ratio of 11.95, a price-to-earnings-growth ratio of 1.34 and a beta of 0.74. The company has a 50-day moving average of $76.66 and a two-hundred day moving average of $100.75. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 70.95%. The business had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the previous year, the firm earned $1.76 EPS. The business’s revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, analysts predict that Zoetis Inc. will post 6.2 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. Zoetis’s payout ratio is presently 35.16%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Weiss Ratings lowered shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Argus reaffirmed a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. TD Cowen decreased their target price on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday, June 30th. Stifel Nicolaus dropped their price target on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research note on Friday, June 26th. Finally, JPMorgan Chase & Co. cut their price target on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a report on Friday. Seven analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $115.50.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 analyst consensus and up from $1.76 a year earlier. The earnings beat provides some support for the stock. Zoetis Surpasses Q2 Earnings Estimates
• Positive Sentiment: JPMorgan lowered its price target from $130 to $115 but maintained an Overweight rating, implying substantial potential upside from recent levels. The target reduction reflects more conservative estimates rather than a bearish long-term view.
• Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with the announcement also describing an expanded finance and operating leadership role. The change may improve execution, but its near-term effect on results is unclear. Zoetis Appoints Jay Saccaro
• Negative Sentiment: Second-quarter revenue was $2.47 billion, below the $2.50 billion consensus and essentially flat year over year. Management cited weaker veterinary traffic, customer price sensitivity and competitive pressure in companion-animal products, with promotions being used to defend market share. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
• Negative Sentiment: Zoetis cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 from expectations near $6.87, and revenue guidance to $9.1–$9.3 billion versus consensus of roughly $9.8 billion. The outlook reduction is the primary reason the stock has declined despite the quarterly earnings beat. Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut

Insider Buying and Selling at Zoetis

In other news, Director Paul Bisaro acquired 2,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This represents a 7.73% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Frank A. Damelio acquired 6,650 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought a total of 11,650 shares of company stock valued at $886,384 over the last quarter. 0.22% of the stock is owned by company insiders.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.